Giada Rizzi

A randomized phase III study evaluating the efficacy and safety of NEPA, a fixed-dose combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy

Matti Aapro, H. S. Rugo, Giada Rizzi et al. · Annals of Oncology · 2014 · 248 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17

Efficacy and safety of NEPA, an oral combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy: a randomized dose-ranging pivotal study

Paul J. Hesketh, Giada Rizzi, Marco Palmas et al. · Annals of Oncology · 2014 · 223 citations · Full text

Medicine, Oncology, Pharmacology +17

A phase III study evaluating the safety and efficacy of NEPA, a fixed-dose combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting over repeated cycles of chemotherapy

Richard J. Gralla, Snežana Bošnjak, A. Hontsa et al. · Annals of Oncology · 2014 · 190 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17

NEPA, a fixed oral combination of netupitant and palonosetron, improves control of chemotherapy-induced nausea and vomiting (CINV) over multiple cycles of chemotherapy: results of a randomized, double-blind, phase 3 trial versus oral palonosetron

Matti Aapro, Meinolf Karthaus, Lee S. Schwartzberg et al. · Supportive Care in Cancer · 2016 · 48 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17

Phase III safety study of intravenous NEPA: a novel fixed antiemetic combination of fosnetupitant and palonosetron in patients receiving highly emetogenic chemotherapy

Lee Schwartzberg, Eric Roeland, Zoran Andrić et al. · Annals of Oncology · 2018 · 39 citations

Medicine, Oncology, Pharmacology +17